Bloomberg Billionaires Index

View profiles for each of the world’s 500 richest people, see the biggest movers, and compare fortunes or track returns.

# 114 Cen Junda $10.9B

Random fact: China has the world's largest number of cancer cases.

Overview

Cen is a shareholder of Jiangsu Hengrui Medicine, a Chinese producer of anti-cancer drugs. The company develops anti-tumor, anti-infective and painkiller drugs, and had revenue of 17.2 billion yuan ($2.6 billion) in 2018. He also owns a stake in Hansoh Pharmaceutical Group, a drug maker that trades publicly in Hong Kong.

As of :
Last change +$230M ( +2.1%)
YTD change +$556M ( +5.4%)
Industry Health Care
Biggest asset 600276 CH Equity
Citizenship China
Wealth Self-made
View net worth over:   Max 1 year 1 quarter 1 month 1 week

Relative Value

Cen Junda's net worth of $10.9B can buy ...

0
troy ounces of gold
0
barrels of crude oil

... and is equivalent to ...

0%
of the GDP of the United States
0%
of the total wealth of the 500 richest people in the world
0%
of the top 100 U.S. college endowments
0%
of the top 200 U.S. executives’ total awarded compensation
0%
of U.S. existing home sales
0
times the median U.S. household income

Latest News

Net Worth Summary

Cash
Private asset
Public asset
Misc. liabilities
Confidence rating:

The majority of Cen's wealth is derived from his 17% stake in Jiangsu Hengrui Medicine, a Chinese manufacturer of anti-cancer medicines. He owns his stake through a holding company, according to the company's 2019 third-quarter report.

Cen also has a 15% stake in Hansoh Pharmaceutical Group, according to a Hong Kong stock exchange filing dated July 17, 2019.

Liu Xiaohan, spokeswoman for the company, declined to comment on the billionaire's net worth.

Biography

Birthdate:
Family: Unknown, No children
Education: Zhejiang University

Cen graduated from Zhejiang University majoring in pharmaceuticals in 1984.

His holding company Apex Medical was a founding shareholder of Hansoh Pharmaceutical Group in 2015, according to the company's prospectus for an initial public offering.

The company began publicly trading in Hong Kong in June 2019. Cen and Zhong Huijuan, chairwoman of the drug maker, are billionaires.

Milestones
  • 1995 Hansoh Pharmaceutical was set up in China.
  • 2000 Jiangsu hengrui started publicly trading in Shanghai.
  • 2011 U.S. approves Jiangsu Hengrui's antineoplastic injection.
  • 2019 Hansoh Pharmaceutical started trading in Hong Kong.